75% of those receiving Skyrizi reported at least a 90% improvement in their plaque psoriasis symptoms.EffectivenessĬlinical studies of adults with plaque psoriasis compared Skyrizi with a placebo (a treatment with no active drug). It’s approved for use in adults with moderate to severe plaque psoriasis who could benefit from systemic therapy or phototherapy. The Food and Drug Administration (FDA) first approved Skyrizi in 2019. They can also teach you how to give yourself injections at home (using the prefilled syringe) if you’d like to start doing it yourself.
When you first start using Skyrizi, your doctor will give you the injections at their office. Skyrizi comes as a prefilled syringe that’s given by subcutaneous injection (under your skin). IL-23 proteins play a part in inflammation that can lead to plaque psoriasis.
It works by attaching to IL-23 proteins and reducing how much inflammation (swelling) occurs in the body. Skyrizi is a type of drug called an interleukin-23 (IL-23) antagonist. Plaque psoriasis often affects the scalp, knees, elbows, and lower back. With this condition, red patches that are thick and scaly appear on the skin. Plaque psoriasis is an autoimmune condition and the most common type of psoriasis. It’s used in adults who could benefit from systemic therapy (drugs that work throughout your body) or phototherapy (light therapy).
Skyrizi is a brand-name prescription medication that’s FDA-approved to treat moderate to severe plaque psoriasis.
0 kommentar(er)
